[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355295-105":59,"doc-detail-355295-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","research-progress-on-the-compositional-characteristics-of-the-tumor-immune-microenvironment-and-immunopredictive-models-in-esophageal-squamous-cell-carcinoma","Research progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma","","Esophageal cancer remains a leading digestive tract malignancy, with esophageal squamous cell carcinoma (ESCC) as its dominant histological subtype. Immunotherapy regimens based on immune checkpoint inhibitors (ICIs) have shown notable benefit in advanced ESCC, yet clinical responses vary markedly because the tumor immune microenvironment (TIME) is heterogeneous. This heterogeneity influences tumor behavior, immunotherapy efficacy, and prognosis. The review synthesizes current knowledge on TIME composition and immunological prediction models and discusses therapeutic strategies that target both features to improve ICI outcomes for ESCC patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/research-progress-on-the-compositional-characteristics-of-the-tumor-immune-microenvironment-and-immunopredictive-models-in-esophageal-squamous-cell-carcinoma/355295/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/research-progress-on-the-compositional-characteristics-of-the-tumor-immune-microenvironment-and-immunopredictive-models-in-esophageal-squamous-cell-carcinoma/355295.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does patient response to immune checkpoint inhibitors vary in ESCC?","Question",{"text":112,"@type":113},"Because the tumor immune microenvironment (TIME) is heterogeneous, which affects immunotherapy efficacy and prognosis across patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the TIME in ESCC composed of?",{"text":117,"@type":113},"It includes tumor cells, immune cell infiltration, immunosuppressive factor expression, and extracellular matrix remodeling, creating an immunosuppressive network.",{"name":119,"@type":110,"acceptedAnswer":120},"How can understanding TIME help improve immunotherapy outcomes?",{"text":121,"@type":113},"By clarifying dynamic TIME alterations and identifying key biomarkers and immunological prediction models that better predict ICI success.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355295,1790168993,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","CANCER BIOLOGY & THERAPY 2026, VOL. 27, NO. 1, 2641263  \n[https://doi.org/10.1080/15384047.2026.2641263](https://doi.org/10.1080/15384047.2026.2641263)  \nREVIEW ARTICLE     \nResearch progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma  \nGongcheng Wanga, Zhenzhen Lia, Siyu Tanb, Jing Mab, Zhiyong Yinc , Juan Dua  and Linni Fanb aBasic Medical Research and Experiment Center, School of Medicine, Yan'an University, Yan'an, China; bDepartment of Pathology, State Key Laboratory of Cancer Biology, Xijing Hospital, Air Force Military Medical University, Xi'an, China; cDepartment of  \nCardiology, Xijing Hospital, Air Force Military Medical University, Xi'an, China  \nABSTRACT  \nEsophageal cancer is one of the most prevalent malignant tumors of the digestive tract, with esophageal squamous cell carcinoma (ESCC) as its main histological type. In recent years, immunotherapeutic regimens centered on immune checkpoint inhibitors (ICIs) have achieved remarkable efficacy in patients with advanced ESCC. However, due to the heterogeneity of the tumor immune microenvironment (TIME), the degree of clinical benefit varies among patients. This heterogeneity not only affects the biological behavior of tumors but also determines the efficacy and prognosis of immunotherapy. Therefore, exploring the interactions between tumor cells and diverse immunological components inside the TIME in ESCC, as well as how to use ICIs to reshape the TIME, may bring new therapeutic opportunities for ESCC patients. This review looks at the important aspects of TIME and immunological prediction models and explores potential therapeutic strategies targeting both, providing a theoretical basis for improving immunotherapy outcomes in ESCC.  \nARTICLE HISTORY  \nReceived 2 December 2025 Revised 2 March 2026 Accepted 2 March 2026  \nKEYWORDS  \nEsophageal squamous cell carcinoma; tumor immune microenvironment; immune checkpoint inhibitors; immune predictive model; immunotherapy  \n1. Introduction  \nSurgery, radiation, chemotherapy, and targeted therapy are the standard treatments for ESCC.1 Survival prospects for individuals with advanced ESCC have improved dramatically as neoadjuvant immunotherapy—a combination of immunotherapy medicines, radiation, and chemotherapy—has become more widely used in treatment. However, only a tiny percentage of patients show a persistent clinical response to ICIs.2 As a result, immunotherapy research and the creation of tailored treatment options have become increasingly important. The TIME is a complex dynamic network that is directly linked to tumor start and progression. It includes not only tumor cells but also immune cell infiltration, immunosuppressive factor expression, and extracellular matrix remodeling. These characteristics all have an impact on how immunotherapy works.3-5 Additionally, aberrant expression of immunological checkpoints such as PD-1/PD-L1 and CTLA-4 is linked to tumor progression and a poor prognosis.6 As a result, learning more about TIME's dynamic alterations and discovering critical biomarkers for predicting ICI success will help researchers develop more effective immunotherapy regimens. This review highlights current studies on the compositional properties of the TIME in ESCC, as well as the creation of immunological prediction models.  \n2. The tumor immune microenvironment of esophageal squamous cell carcinoma  \nThe TIME in ESCC creates an immunosuppressive microenvironment with distinct inhibitory properties.7 As a core component, abnormalities in the composition, phenotype, and functional status of immune cells  \nCONTACT Juan Du  [dujuan123du@126.com](dujuan123du@126.com)  Basic Medical Research and Experiment Center, School of Medicine, Yan'an University, Yan'an, China; Linni Fan  [fanlinni@163.com](fanlinni@163.com)  Department of Pathology, State Key Laboratory of Cancer Biology, Xijing Hospital, Air Force Military Medi","cbCaiaC1Klk2E93v","https://ap.wps.com/l/cbCaiaC1Klk2E93v","pdf",1852771,14,"English","# Introduction\n# The tumor immune microenvironment of esophageal squamous cell carcinoma\n## Tumor-infiltrating lymphocytes (TILs)","[{\"question\":\"Why does patient response to immune checkpoint inhibitors vary in ESCC?\",\"answer\":\"Because the tumor immune microenvironment (TIME) is heterogeneous, which affects immunotherapy efficacy and prognosis across patients.\"},{\"question\":\"What is the TIME in ESCC composed of?\",\"answer\":\"It includes tumor cells, immune cell infiltration, immunosuppressive factor expression, and extracellular matrix remodeling, creating an immunosuppressive network.\"},{\"question\":\"How can understanding TIME help improve immunotherapy outcomes?\",\"answer\":\"By clarifying dynamic TIME alterations and identifying key biomarkers and immunological prediction models that better predict ICI success.\"}]","Research progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma | PDF",1790117455,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe847bf32733beed06ff18c99c5881e1.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4b685588dfc2174418d69060c7c4a2b.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f736b34ce1c4bb559dfb32abd08b3b08.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f0f5e2888fcf05dff0325fbbf4bb1d6.webp",980,1306]